Back to products

Browse products

MedKoo product information:

 Saridegib

Description of Saridegib (IPI-926): Saridegib (IPI-926) is an orally bioavailable, cyclopamine-derived (for structure comparison see Fig 1) inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, Hedgehog pathway inhibitor IPI-926 binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer:    Infinity Pharmaceuticals, Inc.  

Fig 1. Chemical structure comparison between IPI-926 and cyclopamine

IPI-926 is currently developed by Infinity Pharmaceuticals, Inc. Malignant activation of the Hedgehog pathway is implicated in multiple cancer settings and Infinity's development strategy is designed to enable IPI-926 to target a broad range of critical oncology targets - from the tumor cell to the cancer microenvironment. This broadly applicable, targeted approach represents an innovative method for fighting cancer and has potential in treating a range of cancers, including pancreatic cancer, small cell lung cancer, ovarian cancer, bladder cancer, medulloblastoma, basal cell carcinoma, and certain hematological malignancies.

 1. Austad, B.; Bahadoor, A.; Belani, J. D.; Janardanannair, S.; Johannes, C. W.; Keaney, G. F.; Lo, C. K.; Wallerstein, S. L. Enzymatic transamination of cyclopamine analogs. WO2011017551A1.

2. Austad, B.; Behnke, M. L.; Castro, A. C.; Grogan, M. J.; Janardanannair, S.; Lescarbeau, A.; Peluso, S.; Tremblay, M. Preparation of cyclopamine analogs which inhibit the hedgehog pathway for therapeutic use as anticancer agents. US7812164B2.

3. Austad, B.; Janardanannair, S.; Lescarbeau, A.; Tremblay, M. Preparation of cyclopamine analogs for therapeutic use in anticancer pharmaceutical compositions which inhibit the hedgehog pathway. WO2008083248A2, 2008.

4. Austad, B.; Janardanannair, S.; Lescarbeau, A.; Tremblay, M.; Grayzel, D.; Matsui, W. Preparation of cyclopamine analogs for therapeutic use in anticancer pharmaceutical compositions which inhibit the hedgehog pathway. WO2008083252A2, 2008.

5. Austad, B. C. Methods for stereoselective reduction. WO2009086451A1, 2009.

6. Carter, B.; Lee, J. J.; Sheikh, H. Oral formulations of IPI-926. WO2011057222A1.

7. Gould, A.; Missailidis, S., Targeting the Hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the Hedgehog pathway. Mini-Rev. Med. Chem. 11, (3), 200-213.
8. Grayzel, D.; Ross, R.; MacDougall, J. Cancer treatments using hedgehog inhibitors and chemotherapy. WO2009086416A1, 2009.
9. Kottmann, A. H. Shh signaling regulation and methods thereof for upregulating GDNF and treating neurodegenerative disorder. WO2010117800A2.

10. Lin, T. L.; Wang, Q. H.; Brown, P.; Peacock, C.; Merchant, A. A.; Brennan, S.; Jones, E.; McGovern, K.; Neil, W. D.; Sakamoto, K. M.; Matsui, W., Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One 5, (12), e15262.
11. MacDougall, J.; West, K. A. Therapeutic cancer treatments using hedgehog inhibitors combined with EGFR-tyrosine kinase inhibitors. US20100297118A1.

12. McGovern, K. J.; Read, M.; Ross, R. W. Use of hedgehog inhibitor in combination with other chemotherapeutics in cancer treatment. US20100222287A1.

13. Olive, K. P.; Jacobetz, M. A.; Davidson, C. J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M. A.; Caldwell, M. E.; Allard, D.; Frese, K. K.; DeNicola, G.; Feig, C.; Combs, C.; Winter, S. P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W. J.; Chang, A.; Dhara, M.; Wang, L.; Rueckert, F.; Gruetzmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S. R.; Huang, P.; Davies, S. E.; Plunkett, W.; Egorin, M.; Hruban, R. H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D. A., Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science (Washington, DC, U. S.) 2009, 324, (5933), 1457-1461.

14. Olive, K. P.; Tuveson, D. Hedgehog pathway inhibitors. WO2010085654A1.

15. Tao, C.; Desai, N. P.; Soon-Shiong, P. Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors for treating proliferative disease such as cancer. WO2011025838A1.
16. Travaglione, V.; Macdougall, J.; McGovern, K. J. Methods and compositions for treating hedgehog-associated cancers. WO2011063309A1.

17. Tremblay, M. R.; Lescarbeau, A.; Grogan, M. J.; Tan, E.; Lin, G.; Austad, B. C.; Yu, L.-C.; Behnke, M. L.; Nair, S. J.; Hagel, M.; White, K.; Conley, J.; Manna, J. D.; Alvarez-Diez, T. M.; Hoyt, J.; Woodward, C. N.; Sydor, J. R.; Pink, M.; MacDougall, J.; Campbell, M. J.; Cushing, J.; Ferguson, J.; Curtis, M. S.; McGovern, K.; Read, M. A.; Palombella, V. J.; Adams, J.; Castro, A. C., Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926). J. Med. Chem. 2009, 52, (14), 4400-4418.